

George Ioannou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8041323/publications.pdf>

Version: 2024-02-01

151
papers

11,053
citations

26567

56
h-index

32761

100
g-index

155
all docs

155
docs citations

155
times ranked

13786
citing authors

#	ARTICLE	IF	CITATIONS
1	NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. <i>Journal of Hepatology</i> , 2017, 66, 1037-1046.	1.8	738
2	HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, 25-32.	1.8	393
3	Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001–2013. <i>Gastroenterology</i> , 2015, 149, 1471-1482.e5.	0.6	368
4	The Role of Cholesterol in the Pathogenesis of NASH. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 84-95.	3.1	347
5	Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10–131 US Veterans With SARS-CoV-2 Infection. <i>JAMA Network Open</i> , 2020, 3, e2022310.	2.8	305
6	The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999-2002. <i>American Journal of Gastroenterology</i> , 2006, 101, 76-82.	0.2	286
7	Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 67-74.	2.4	283
8	Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2011, 141, 1393-1403.e5.	0.6	279
9	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , 2019, 157, 1264-1278.e4.	0.6	252
10	Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Allocation System and Predictors of Survival. <i>Gastroenterology</i> , 2008, 134, 1342-1351.	0.6	240
11	Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 938-945.e4.	2.4	234
12	Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. <i>Hepatology</i> , 2013, 57, 81-92.	3.6	219
13	Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. <i>Hepatology</i> , 2006, 43, 1145-1151.	3.6	207
14	Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. <i>Journal of Lipid Research</i> , 2011, 52, 1626-1635.	2.0	196
15	Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. <i>Gastroenterology</i> , 2016, 151, 457-471.e5.	0.6	195
16	The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. <i>Gastroenterology</i> , 2004, 126, 1293-1301.	0.6	182
17	Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. <i>Journal of Lipid Research</i> , 2013, 54, 1326-1334.	2.0	180
18	The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. <i>Hepatology</i> , 2013, 57, 249-257.	3.6	171

#	ARTICLE	IF	CITATIONS
19	Epidemiology and risk-stratification of NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2021, 75, 1476-1484.	1.8	160
20	Terlipressin in acute oesophageal variceal haemorrhage. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 53-64.	1.9	153
21	Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. <i>Gastroenterology</i> , 2016, 150, 441-453.e6.	0.6	150
22	What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?. <i>Gastroenterology</i> , 2019, 156, 446-460.e2.	0.6	149
23	Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. <i>Liver Transplantation</i> , 2013, 19, 634-645.	1.3	143
24	Hepatitis B Virus in the United States: Infection, Exposure, and Immunity Rates in a Nationally Representative Survey. <i>Annals of Internal Medicine</i> , 2011, 154, 319.	2.0	142
25	Is Obesity Associated With Anemia of Chronic Disease? A Population-based Study. <i>Obesity</i> , 2008, 16, 2356-2361.	1.5	141
26	Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population. <i>Hepatology</i> , 2009, 50, 175-184.	3.6	138
27	Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. <i>Nature Communications</i> , 2018, 9, 4490.	5.8	135
28	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1253-1263.e2.	0.6	131
29	Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. <i>Diabetes Care</i> , 2017, 40, 1173-1180.	4.3	130
30	Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. <i>Liver Transplantation</i> , 2012, 18, 29-37.	1.3	124
31	Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. <i>Journal of Hepatology</i> , 2019, 71, 523-533.	1.8	124
32	Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 32-39.	1.8	121
33	Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. <i>Journal of Hepatology</i> , 2018, 69, 1088-1098.	1.8	119
34	Development and validation of a model predicting graft survival after liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1594-1606.	1.3	117
35	Iron deficiency and gastrointestinal malignancy: a population-based cohort study. <i>American Journal of Medicine</i> , 2002, 113, 276-280.	0.6	115
36	Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. <i>Journal of Lipid Research</i> , 2017, 58, 1067-1079.	2.0	111

#	ARTICLE	IF	CITATIONS
37	Is obesity a risk factor for cirrhosis-related death or hospitalization? a population-based cohort study. <i>Gastroenterology</i> , 2003, 125, 1053-1059.	0.6	107
38	Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. <i>Journal of Hepatology</i> , 2013, 59, 144-152.	1.8	105
39	Association between serum uric acid level and chronic liver disease in the United States. <i>Hepatology</i> , 2010, 52, 578-589.	3.6	102
40	Improved Surveillance for Hepatocellular Carcinoma With a Primary Care-“Oriented Clinical Reminder. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 172-179.	2.4	92
41	HCC surveillance after SVR in patients with F3/F4 fibrosis. <i>Journal of Hepatology</i> , 2021, 74, 458-465.	1.8	86
42	Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 73, 204-218.	3.6	83
43	No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1128-1139.e6.	0.6	80
44	Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. <i>Hepatology Communications</i> , 2022, 6, 12-35.	2.0	80
45	Portal Vein Thrombosis Is Not Associated With Increased Mortality Among Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 585-593.	2.4	79
46	Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0204412.	1.1	77
47	Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. <i>JAMA Network Open</i> , 2020, 3, e2015626.	2.8	75
48	The selective peroxisome proliferator-activated receptor-δ agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. <i>Hepatology Communications</i> , 2017, 1, 663-674.	2.0	69
49	Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. <i>Gastroenterology</i> , 2005, 128, 627-635.	0.6	68
50	The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. <i>Hepatology</i> , 2017, 65, 426-438.	3.6	68
51	Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 1510-1519.	2.0	66
52	Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality. <i>Hepatology</i> , 2021, 74, 322-335.	3.6	66
53	TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival. <i>Clinical Science</i> , 2017, 131, 2145-2159.	1.8	64
54	Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. <i>Journal of Lipid Research</i> , 2015, 56, 277-285.	2.0	63

#	ARTICLE	IF	CITATIONS
55	Survival of Liver Transplant Recipients With Hemochromatosis in the United States. <i>Gastroenterology</i> , 2007, 133, 489-495.	0.6	62
56	Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. <i>Journal of Diabetes and Its Complications</i> , 2007, 21, 363-370.	1.2	59
57	Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States. <i>Gastroenterology</i> , 2015, 149, 669-680.	0.6	59
58	Machine learning models to predict disease progression among veterans with hepatitis C virus. <i>PLoS ONE</i> , 2019, 14, e0208141.	1.1	59
59	Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. <i>Drug and Alcohol Dependence</i> , 2016, 169, 101-109.	1.6	58
60	Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anemia. <i>American Journal of Medicine</i> , 2002, 113, 281-287.	0.6	57
61	Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs. <i>Epidemiologic Reviews</i> , 2015, 37, 131-143.	1.3	53
62	Is <i>Helicobacter pylori</i> seropositivity related to body mass index in the United States?. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 765-772.	1.9	52
63	Impact of exposure to patients with COVID-19 on residents and fellows: an international survey of 1420 trainees. <i>Postgraduate Medical Journal</i> , 2021, 97, 706-715.	0.9	52
64	Racial differences in the relationship between hepatitis C infection and iron stores. <i>Hepatology</i> , 2003, 37, 795-801.	3.6	51
65	Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17,487 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 686-693.	0.8	50
66	Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2019, 3, 776-791.	2.0	50
67	Are Patients with Child-Pugh A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?. <i>American Journal of Transplantation</i> , 2012, 12, 706-717.	2.6	47
68	Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1201-1212.	1.9	47
69	Similar Effectiveness of Boceprevir and Telaprevir Treatment Regimens for Hepatitis C Virus Infection on the Basis of a Nationwide Study of Veterans. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1371-1380.	2.4	46
70	Serum bilirubin and colorectal cancer risk: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1637-1642.	1.9	41
71	Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 972-978.	2.4	41
72	COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System. <i>Annals of Internal Medicine</i> , 2022, 175, 352-361.	2.0	41

#	ARTICLE	IF	CITATIONS
73	Association Between Transjugular Intrahepatic Portosystemic Shunt and Survival in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 118-123.	2.4	40
74	Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. <i>Obesity</i> , 2017, 25, 155-165.	1.5	40
75	Survival after orthotopic liver transplantation: The impact of antibody against hepatitis B core antigen in the donor. <i>Liver Transplantation</i> , 2009, 15, 1343-1350.	1.3	35
76	Risk Factors for Testing Positive for Severe Acute Respiratory Syndrome Coronavirus 2 in a National United States Healthcare System. <i>Clinical Infectious Diseases</i> , 2021, 73, e3085-e3094.	2.9	35
77	Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. <i>PLoS ONE</i> , 2017, 12, e0189965.	1.1	35
78	Use of Antibiotics Among Patients With Cirrhosis and Upper Gastrointestinal Bleeding Is Associated With Reduced Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1629-1637.e1.	2.4	34
79	Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1312-1320.	1.4	34
80	Incidence and Risk Factors of Postoperative Mortality and Morbidity After Elective Versus Emergent Abdominal Surgery in a National Sample of 8193 Patients With Cirrhosis. <i>Annals of Surgery</i> , 2021, 274, e345-e354.	2.1	33
81	Development of COVIDVax Model to Estimate the Risk of SARS-CoV-2-Related Death Among 7.6 Million US Veterans for Use in Vaccination Prioritization. <i>JAMA Network Open</i> , 2021, 4, e214347.	2.8	33
82	Cholelithiasis, Cholecystectomy, and Liver Disease. <i>American Journal of Gastroenterology</i> , 2010, 105, 1364-1373.	0.2	30
83	Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system. <i>EClinicalMedicine</i> , 2022, 45, 101326.	3.2	29
84	Exercise retards hepatocarcinogenesis in obese mice independently of weight control. <i>Journal of Hepatology</i> , 2020, 73, 140-148.	1.8	28
85	BMI and Outcomes of SARS-CoV-2 Among US Veterans. <i>Obesity</i> , 2021, 29, 900-908.	1.5	28
86	Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. <i>Hepatology Communications</i> , 2022, 6, 780-794.	2.0	28
87	Effects of menopause and hormone replacement therapy on the associations of hyperuricemia with mortality. <i>Atherosclerosis</i> , 2013, 226, 220-227.	0.4	27
88	Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 589-596.	1.4	26
89	Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. <i>Metabolites</i> , 2020, 10, 168.	1.3	26
90	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	3.6	26

#	ARTICLE	IF	CITATIONS
91	Relationship Between Transferrin-Iron Saturation, Alcohol Consumption, and the Incidence of Cirrhosis and Liver Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 624-629.	2.4	25
92	Associations Between Alcohol Use and Liver-Related Outcomes in a Large National Cohort of Patients With Cirrhosis. <i>Hepatology Communications</i> , 2021, 5, 2080-2095.	2.0	25
93	No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. <i>Gut</i> , 2021, 70, gutjnl-2019-319867.	6.1	24
94	Genetic ablation of <i>Cyp8b1</i> preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 314, E418-E432.	1.8	22
95	Hepatitis C eradication with direct-acting antivirals reduces the risk of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 364-373.	1.9	22
96	PM2.5 air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample. <i>Environmental Research</i> , 2022, 213, 113611.	3.7	22
97	Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. <i>Drug and Alcohol Dependence</i> , 2018, 188, 79-85.	1.6	21
98	Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2394-2406.	1.1	21
99	Disparities in Waitlist and Posttransplantation Outcomes in Liver Transplant Registrants and Recipients Aged 18 to 24 Years. <i>Transplantation</i> , 2017, 101, 1616-1627.	0.5	20
100	Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1197-1206.e7.	2.4	20
101	Trends Over Time in the Risk of Adverse Outcomes Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 416-426.	2.9	20
102	Dietary Cholesterol Intake Is Associated With Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1661-1666.e3.	2.4	19
103	Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. <i>Journal of Viral Hepatitis</i> , 2017, 24, 966-975.	1.0	18
104	Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. <i>Liver Transplantation</i> , 2017, 23, 652-662.	1.3	18
105	Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1003.	3.8	17
106	Chronic hepatitis B infection: A global disease requiring global strategies. <i>Hepatology</i> , 2013, 58, 839-843.	3.6	16
107	Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy. <i>Clinical Liver Disease</i> , 2019, 13, 6-12.	1.0	16
108	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 974-983.	2.4	16

#	ARTICLE	IF	CITATIONS
109	Changes in the associations of race and rurality with SARS-CoV-2 infection, mortality, and case fatality in the United States from February 2020 to March 2021: A population-based cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003807.	3.9	16
110	Fast macromolecular proton fraction mapping of the human liver <i>in vivo</i> for quantitative assessment of hepatic fibrosis. <i>NMR in Biomedicine</i> , 2015, 28, 1716-1725.	1.6	15
111	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	2.4	15
112	Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV coinfection in a nationwide study of 619 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1373-1384.	1.9	14
113	The Impact of Direct-acting Antiviral Therapy for Hepatitis C on Hepatocellular Carcinoma Risk. <i>Current Hepatology Reports</i> , 2018, 17, 377-384.	0.4	14
114	Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system. <i>PLoS ONE</i> , 2021, 16, e0259696.	1.1	14
115	The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System. <i>American Journal of Gastroenterology</i> , 2022, 117, 678-684.	0.2	14
116	Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 850-859.	1.8	13
117	SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. <i>Contemporary Clinical Trials</i> , 2021, 104, 106367.	0.8	13
118	Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1717-1727.	1.9	13
119	Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1723-1738.e5.	2.4	12
120	Can Computerized Brain Training Games be Used to Identify Early Cognitive Impairment in Cirrhosis?. <i>American Journal of Gastroenterology</i> , 2014, 109, 316-323.	0.2	11
121	Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 667-675.	0.8	11
122	Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-acting Antivirals. <i>Hepatology Communications</i> , 2019, 3, 1124-1136.	2.0	11
123	Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-acting Antivirals for Hepatitis C Treatment. <i>Hepatology Communications</i> , 2020, 4, 314-324.	2.0	11
124	Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 577-584.	0.8	10
125	Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 411-415.	0.2	9
126	A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma "Initial, Maximum, Last Classification. <i>Liver Transplantation</i> , 2019, 25, 559-570.	1.3	7

#	ARTICLE	IF	CITATIONS
127	No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 47-52.	0.8	7
128	Risk factors for adverse outcomes in emergency versus nonemergency open umbilical hernia repair and opportunities for elective repair in a national cohort of patients with cirrhosis. <i>Surgery</i> , 2022, 172, 184-192.	1.0	7
129	Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score. <i>Gastroenterology</i> , 2022, 163, 1104-1106.e3.	0.6	7
130	Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfecting patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 123-129.	0.8	6
131	Prevalence and Management of Chronic Hepatitis C Virus Infection in Women. <i>Medical Clinics of North America</i> , 2015, 99, 575-586.	1.1	6
132	For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective?. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1732-1735.	2.4	5
133	Prevalence of Hepatitis B Virus Exposure in the Veterans Health Administration and Association With Military-Related Risk Factors. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 954-962.e6.	2.4	5
134	Beyond obesity: Is cholesterol-induced liver injury the cause of nonalcoholic steatohepatitis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1412-1414.	1.4	4
135	Reply to: "Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything" and "More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations". <i>Journal of Hepatology</i> , 2018, 68, 219-220.	1.8	4
136	Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection. <i>British Journal of Nutrition</i> , 2016, 115, 193-201.	1.2	3
137	Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF- κ B or Akt/mTORC1. <i>Journal of Clinical and Translational Research</i> , 2016, 2, 26-37.	0.3	3
138	How can we improve prioritization for liver transplantation in patients with hepatocellular carcinoma?. <i>Liver Transplantation</i> , 2016, 22, 1321-1323.	1.3	2
139	Bilirubin and colorectal cancer: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1504-1504.	1.9	1
140	Reply. <i>Hepatology</i> , 2017, 65, 2125-2126.	3.6	1
141	Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. <i>Hepatology Communications</i> , 2021, 5, 1465-1468.	2.0	1
142	Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 347.	1.5	1
143	Serum bilirubin and risk of colorectal cancer: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1259-1261.	1.9	0
144	Reply: Towards a better liver transplant allocation system. <i>Liver Transplantation</i> , 2007, 13, 937-937.	1.3	0

#	ARTICLE	IF	CITATIONS
145	Reply. Gastroenterology, 2016, 150, 535-537.	0.6	0
146	Editorial: hepatocellular carcinoma in the absence of cirrhosisâ€”a nightmare without solution. Alimentary Pharmacology and Therapeutics, 2019, 50, 1062-1063.	1.9	0
147	Editorial: benefits of <scp>HCV</scp> eradication beyond the liver. Alimentary Pharmacology and Therapeutics, 2019, 49, 1364-1365.	1.9	0
148	Reply. Gastroenterology, 2019, 156, 1218-1220.	0.6	0
149	Reply to: â€œIndividual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatmentâ€. Journal of Hepatology, 2019, 70, 211-212.	1.8	0
150	Reply. Clinical Gastroenterology and Hepatology, 2020, 19, 1992-1993.	2.4	0
151	Editorial: is there a â€œprecursorâ€ HCC lesion and can it be detected by hepatobiliary contrastâ€”enhanced magnetic resonance imaging?. Alimentary Pharmacology and Therapeutics, 2021, 54, 202-203.	1.9	0